ClinicalTrials.gg
RecruitingNCT07283887Updated Dec 16, 2025

Romosozumab and Denosumab, Alone or Combined, in Postmenopausal Osteoporosis

A Phase 4 interventional study of Denosumab and Romosozumab in Osteoporosis, sponsored by National Taiwan University Hospital. Recruiting at 1 site in Taiwan. Open to female participants aged 50 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-12-16.

Sponsored by National Taiwan University Hospital · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Jul 2026, 3 months ago, but the record still lists the study as recruiting.
  • Started Dec 2025; still recruiting 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
90
Allocation
Randomized
Ages
50 Years to 80 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 64 studies testing denosumab in Osteoporosis — 8 open to participants now, 11 under way, 2 of them phase 3. Denosumab · Osteoporosis.

Planned enrollment
32nd of 64
90 · median 90
Started
2025
with 3 others
Phase 4
19 of 64
5 open now
Primary completion
2026-07
later than 1 of 10 live
Registered
63rd of 64
by date
Lead sponsor
2 of 64
National Taiwan University Hospital

Among the 64 studies testing denosumab in Osteoporosis, this one is the 32nd largest by planned enrollment, is one of 4 that started in 2025, is one of 19 in phase 4, reaches primary completion later than 1 of the 10 other live ones, and was the 63rd registered.

Osteoporosis

1,602 studies on the registry are indexed under Osteoporosis; 209 are open to participants now.

Browse Osteoporosis studies →

Open to participants now

8 of the 64 studies testing denosumab in Osteoporosis are open now, in 8 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 8 open studies →

About denosumab

Denosumab: first FDA approval 2010 (PROLIA), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 133 Osteoporosis studies recruiting now, 77 (58%) set no upper age limit and 20 (15%) stop at 75 or younger; 9 take children under 18; 36 take healthy volunteers.

This study: 50 Years to 80 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 64 studies testing denosumab in Osteoporosis, or all of them as a file.
02

Study summary

Osteoporosis is a lifelong chronic condition requiring long-term management. Conventional first-line anti-resorptive therapies often yield slow BMD improvement and may plateau after years of treatment. Recent AACE/ACE guidelines recommend anabolic agents as initial therapy in patients with severe osteoporosis or very high fracture risk; however, even anabolic monotherapy may be insufficient, with many patients failing to reach a T-score ≥ -2.5. To address this unmet need, we propose a pilot study exploring cyclic treatment using romosozumab combined with denosumab, compared with standard denosumab monotherapy. In addition to monitoring biochemical bone markers and BMD, we will incorporate imaging feature extraction from X-rays and AI-based radiomic analysis to identify imaging biomarkers that may support precision treatment strategies.

This single-center, open-label, 6-month, randomized pilot trial will enroll 90 postmenopausal women with osteoporosis (T-score ≤ -2.5) at NTUH Yunlin Branch, randomized 1:1:1 into three arms: denosumab alone, romosozumab alone, or combined therapy. The primary endpoint is percent change in lumbar spine BMD at 6 months; secondary outcomes include hip and femoral neck BMD, bone turnover markers (CTX, P1NP), fracture incidence, and adverse events. Results will estimate effect size and synergy to inform future large-scale RCTs and clinical application.

03

Conditions studied

  • Osteoporosis

Browse trials for

Keywords

  • romosozumab
  • denosumab
  • combination therapy
04

Who can participate

Ages eligible
50 Years to 80 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • women over 50 years of age eligible for osteoporosis treatment, defined as having a bone mineral density (BMD) T-score ≤ -2.5 at the lumbar spine, total hip, or femoral neck, and who have never received osteoporosis medications (including both injectable and oral agents); or those who have used oral osteoporosis medications for no more than six months and have discontinued them for at least three months; or those who have previously received injectable osteoporosis drugs but have discontinued them for more than two years.

Exclusion criteria

Exclusion Criteria:

  • Age >80 years; continuous use; secondary osteoporosis; current use of medications affecting bone metabolism; ongoing hormone replacement therapy; metabolic bone disorders; active cancer; hypocalcemia; continued use of any osteoporosis treatment without an adequate ; to denosumab; and contraindications to romosozumab, such as a history of myocardial infarction or stroke within the past year.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
90 participants (estimated)

Study arms

  • Active comparator
    Denosumab

    After study entry, a single dose of denosumab will be administered for a six-month duration.

    Drug: Denosumab

  • Active comparator
    Romosozumab

    After study entry, romosozumab will be administered monthly for six months.

    Drug: Romosozumab

  • Experimental
    Romosozumab plus denosumab

    After study entry, a single dose of denosumab will be administered. Romosozumab will be given monthly for six months.

    Drug: Denosumab · Drug: Romosozumab

Interventions

  • After study entry, a single dose of denosumab will be administered for a six-month duration.

  • After study entry, romosozumab will be administered monthly for six months.

06

What researchers measure

Primary outcomes

  1. 6-Month Percentage Change in PA Spine BMD

    Percentage change from baseline in PA spine BMD at 6 months

    Time frame: 6 months

Secondary outcomes

  1. 6-Month Percentage Change in femoral neck BMD

    Percentage change from baseline in femoral neck BMD at 6 months

    Time frame: 6 months

  2. 6-Month Percentage Change in total hip BMD

    Percentage change from baseline in total hip BMD at 6 months

    Time frame: 6 months

  3. Percentage Change in Serum CTX at 6 Months

    Six-month percentage change in CTX from baseline.

    Time frame: 6 months

  4. Percentage Change in Serum P1NP at 6 Months

    Six-month percentage change in P1NP from baseline.

    Time frame: 6 months

Other outcomes

  1. Changes in Bone Metabolism Markers

    Changes in OPG, RANKL, and Osteocalcin

    Time frame: 6 months

  2. Radiographic Changes at Hip and Spine

    X-ray Changes in Hip, Spine, and Pelvis

    Time frame: 6 months

  3. Incidence of Clinical Osteoporotic Fractures

    Clinical Osteoporotic Fracture Rate

    Time frame: 6 months

  4. Change in Quality of Life

    Change in Quality of Life, measured by EQ5D5L

    Time frame: 6 months

  5. Safety Outcome: Adverse Events

    any Adverse Events

    Time frame: 6 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2025 (actual). Primary completion is estimated for Jul 2026, 7 months after the start.

Of 55 non-industry phase 4 interventional studies under Osteoporosis, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 71. This study's planned 7 months is below that.

Counting every sponsor, half of 65 studies reached it within 46 months; a quarter within 29 and three quarters within 75.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 7, 2025
First posted
Dec 16, 2025
StartActual
Dec 3, 2025
Primary completionEst.
Jul 31, 2026
CompletionEst.
Jul 31, 2026
Last update
Dec 16, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 16, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07283887
Responsible party
Sponsor
First posted
Dec 16, 2025
Start date
Dec 3, 2025
Primary completion
Jul 31, 2026 (estimated)
Completion
Jul 31, 2026 (estimated)
Last update
Dec 16, 2025

Study contacts

Shau-Huai Fu, PhD
Contact
b90401045@gmail.com
+886972655734

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Denosumab · Romosozumab

Start the discussion